SCHEMBL6796331

SCHEMBL6796331

CCOC(=O)N1CCC(O)(c2ccc(Cl)c(Cl)c2)CC1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.59
MAPK1 P28482 1/20 0.59
HTT P42858 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.56
OPRM1 P35372 1/20 0.56
DRD2 P14416 1/20 0.47
ALDH1A1 P00352 3/20 0.47
HPGD P15428 1/20 0.47
APP P05067 1/20 0.46
SLC6A2 P23975 1/20 0.46
SLC6A4 P31645 1/20 0.46
SLC6A3 Q01959 1/20 0.46
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
POLB P06746 1/20 0.45
TSHR P16473 2/20 0.44
LMNA P02545 1/20 0.44
KDM4E B2RXH2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2269302 0.86 OPRM1 (0.56) L3MBTL1OPRM1DRD2SLC6A2SLC6A4
SCHEMBL29995634 0.84 NOS2 (0.54) KMT2AMEN1
SCHEMBL29087312 0.84 NOS2 (0.54) KMT2AMEN1
SCHEMBL654359 0.83 CCR5 (0.47) DRD2KMT2AMEN1POLBTSHR
SCHEMBL9311071 0.81 OPRM1 (0.57) MAPTHTTL3MBTL1OPRM1ALDH1A1
SCHEMBL3387438 0.80 DRD2 (0.50) OPRM1DRD2SLC6A3KMT2AMEN1
SCHEMBL9311212 0.79 OPRM1 (0.52) L3MBTL1OPRM1DRD2SLC6A2SLC6A4
SCHEMBL30702477 0.79 NOS2 (0.52) L3MBTL1OPRM1ALDH1A1APPKMT2A
SCHEMBL9529108 0.78 APP (0.59) MAPTHTTL3MBTL1OPRM1ALDH1A1
SCHEMBL3852309 0.77 DRD2 (0.54) OPRM1DRD2ALDH1A1HPGDSLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040044007-A1 Indoline derivatives H. LUNDBECK A/S (DK) 2004-03-04 US disclosed
EP-1345921-A1 3-INDOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC AND NEUROLOGIC DISORDERS H. Lundbeck A/S (DK) 2003-09-24 EP disclosed
WO-2002051833-A1 3-INDOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC AND NEUROLOGIC DISORDERS H. LUNDBECK A/S (DK) 2002-07-04 WO disclosed
EP-0861832-A1 Novel tetrahydropyridine derivatives SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) 1998-09-02 EP disclosed
US-5410058-A Exhibit high affinity and specificity to alpha receptors; useful in treating some psychoses SHIONOGI & CO., LTD. (JP) 1995-04-25 US disclosed
US-5362873-A Tetrahydropyridine derivatives SHIONOGI & CO., LTD. (JP) 1994-11-08 US disclosed
US-5243051-A Treatment of psychological disorders SHIONIGI & CO., LTD. (JP) 1993-09-07 US disclosed
US-5149817-A Psychotropic agents SHIONOGI & CO., LTD. (JP) 1992-09-22 US disclosed
EP-0445701-A1 Novel tetrahydropyridine derivatives SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) 1991-09-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044007-A1 Indoline derivatives CNR1, GRIN2C, HTR3C MAPT 1673/4885MAPK1 1122/4885HTT 345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.